In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulted in a median progression-free survival of 9.2 months and a median overall survival of 12.6 months, in an open-label phase I/II study led by Zev A. Wainberg, MD, of the University of California Los Angeles.
The findings were presented during the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancers 2020 Virtual by Dr. Wainberg, who noted the need for life-prolonging and well-tolerated therapies for persons with pancreatic cancer, who typically present with metastatic disease and have a poor prognosis. Read more . . .